BCRX
BioCryst Pharmaceuticals Inc
8.40$
+5.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.7% | -0.7% | +17.9% | +7.1% | +12.3% | +10.6% | +12.2% | -2.4% | +155.1% | -61.5% | +39.5% | – | |
| – | +44.1% | -22.7% | +34.3% | +90.0% | +89.9% | -25.5% | -38.7% | -9.9% | +293.2% | +6,990.9% | -99.5% | – | |
| – | +7.2% | -0.3% | +17.6% | +5.8% | +10.1% | +12.4% | +13.9% | -2.3% | +152.8% | -237.8% | – | – | |
| – | +49.4% | -33.6% | -19.1% | +9.2% | +20.4% | -24.6% | +16.4% | +2.0% | -6.9% | +46.4% | -13.8% | – | |
| – | -1.3% | +18.8% | +3.1% | +6.3% | +23.6% | +2.5% | +6.0% | -5.0% | +15.4% | -1.3% | -32.3% | – | |
| – | +37.8% | -21.2% | -6.7% | +7.4% | +22.4% | -7.8% | +9.2% | -2.7% | +7.4% | +13.3% | -25.1% | – | |
| – | – | – | – | -12.2% | -158.6% | – | +40.3% | -0.7% | +779.9% | -369.4% | – | – | |
| – | -10.1% | -0.3% | +0.9% | +0.4% | -1.5% | -3.9% | -8.1% | -8.9% | -28.1% | +39.9% | +9.8% | – | |
| – | – | – | – | – | – | – | +755.7% | +87.0% | +1,944.7% | -390.6% | – | – | |
| – | -533.6% | – | -52.9% | +240.7% | +37.2% | -9.7% | +93.0% | -154.9% | – | -53.8% | +7.5% | – | |
| – | – | – | – | – | – | – | +15,790.6% | +153.7% | +1,805.9% | -393.6% | – | – | |
| – | – | – | – | -6.8% | -110.5% | – | +15.5% | +13.1% | +728.6% | -363.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.